MAIA Biotechnology Files 8-K: Material Agreement & Equity Sales
Ticker: MAIA · Form: 8-K · Filed: Oct 29, 2024 · CIK: 1878313
Sentiment: neutral
Topics: material-agreement, equity-sale, sec-filing
TL;DR
MAIA Bio inked a big deal & sold some stock, filing shows.
AI Summary
MAIA Biotechnology, Inc. announced on October 28, 2024, that it entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and other events, including financial statements and exhibits. This filing details significant corporate actions and financial disclosures for MAIA Biotechnology.
Why It Matters
This filing indicates significant corporate activity for MAIA Biotechnology, including a new material agreement and equity transactions, which could impact its financial standing and future operations.
Risk Assessment
Risk Level: medium — The filing involves material definitive agreements and unregistered equity sales, which can carry inherent risks related to deal terms and share dilution.
Key Numbers
- 001-41455 — SEC File Number (Identifies the company's filing with the SEC.)
- 83-1495913 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- MAIA Biotechnology, Inc. (company) — Registrant
- October 28, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 444 West Lake Street, Suite 1700 (address) — Principal executive offices
- Chicago, IL 60606 (address) — Principal executive offices
FAQ
What is the nature of the material definitive agreement entered into by MAIA Biotechnology?
The filing indicates the entry into a material definitive agreement but does not specify its nature in the provided text.
What were the details of the unregistered sales of equity securities?
The filing mentions unregistered sales of equity securities as an event but does not provide specific details on the amount or terms in the provided text.
What are the key items reported in this 8-K filing?
The key items reported are Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, and Financial Statements and Exhibits.
When was the earliest event reported in this filing?
The earliest event reported was on October 28, 2024.
Where are MAIA Biotechnology's principal executive offices located?
MAIA Biotechnology's principal executive offices are located at 444 West Lake Street, Suite 1700, Chicago, IL 60606.
Filing Stats: 1,364 words · 5 min read · ~5 pages · Grade level 13.3 · Accepted 2024-10-29 06:17:01
Key Financial Figures
- $0.0001 — f the Company's common stock, par value $0.0001 per share (" Common Stock "), and (ii)
- $2 — f Common Stock, at a price per share of $2.259, for an aggregate purchase price of
- $1,913,337 — gregate purchase price of approximately $1,913,337. The Warrants are exercisable at a pri
- $2.259 — e " Warrants ") at a price per share of $2.259 for an aggregate purchase price of appr
- $525,895 — gregate purchase price of approximately $525,895. The Director Warrants are exercisable
- $2.51 — Warrants are exercisable at a price of $2.51 per share, which price represents the g
- $225,900 — gregate purchase price of approximately $225,900; Company director Ramiro Guerrero subsc
- $200,000 — gregate purchase price of approximately $200,000; Company director Steven Chaouki subscr
- $50,000 — gregate purchase price of approximately $50,000; and Company director Cristian Luput su
- $90,360 — gregate purchase price of approximately $90,360 The Shares and the Warrants (and the
- $4.4 m — ferings is expected to be approximately $4.4 million, prior to deducting offering expe
Filing Documents
- d902975d8k.htm (8-K) — 35KB
- d902975dex41.htm (EX-4.1) — 72KB
- d902975dex42.htm (EX-4.2) — 64KB
- d902975dex101.htm (EX-10.1) — 306KB
- d902975dex991.htm (EX-99.1) — 8KB
- 0001193125-24-246134.txt ( ) — 739KB
- maia-20241028.xsd (EX-101.SCH) — 3KB
- maia-20241028_lab.xml (EX-101.LAB) — 18KB
- maia-20241028_pre.xml (EX-101.PRE) — 11KB
- d902975d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits. Exhibit No. Description 4.1 Form of Investor Warrant 4.2 Form of Director Warrant 10.1* Form of Securities Purchase Agreement 99.1 Press Release dated October 28, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). * The schedules (and similar attachments) to this exhibit have been omitted from this filing pursuant to Item 601(b)(10) of Regulation S-K. The Company agrees to furnish a supplemental copy of any omitted schedule (or similar attachment) to the Securities and Exchange Commission upon request. 3
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: October 29, 2024 MAIA BIOTECHNOLOGY, INC. By: /s/ Vlad Vitoc Name: Vlad Vitoc Title: Chief Executive Officer 4